Clinical OncologyClinical Oncologyhttp://hdl.handle.net/10541/567362024-03-29T05:26:44Z2024-03-29T05:26:44ZThe role of positron emission tomography in management of small cell lung cancer.Thomson, David JHulse, PaulLorigan, Paul CFaivre-Finn, Corinnehttp://hdl.handle.net/10541/2309152019-08-30T13:29:45Z2011-08-01T00:00:00ZThe role of positron emission tomography in management of small cell lung cancer.
Thomson, David J; Hulse, Paul; Lorigan, Paul C; Faivre-Finn, Corinne
Accurate radiological staging of small-cell lung cancer (SCLC) is of paramount importance in selection of individual patients with limited stage disease for potentially curative treatment while avoiding toxic treatment in those with distant metastatic disease. [(18)F] flurodeoxy-D-glucose (FDG) positron emission tomography (PET) is an attractive tool for this purpose but there is limited evidence to support its use in the routine staging of SCLC. Whether therapeutic decisions based on FDG-PET imaging should be made remains uncertain. There is only preliminary evidence for use of FDG-PET as a prognostic biomarker, in the assessment of response to treatment and delineation of disease in conformal radiation planning.
2011-08-01T00:00:00ZPrediction of post-treatment trismus in head and neck cancer patients.Lee, RanaSlevin, Nicholas JMusgrove, BrianSwindell, RicMolassiotis, Alexanderhttp://hdl.handle.net/10541/2309122019-08-30T13:15:35Z2011-07-25T00:00:00ZPrediction of post-treatment trismus in head and neck cancer patients.
Lee, Rana; Slevin, Nicholas J; Musgrove, Brian; Swindell, Ric; Molassiotis, Alexander
Our aim was to establish the incidence of trismus over time, together with risk factors (including quality of life (QoL)) for the prediction of trismus after treatment in patients with cancer of the head and neck. It was a longitudinal study of 152 patients accepted for primary operation who attended the head and neck cancer clinic of a tertiary referral cancer centre in the United Kingdom. A total of 87 patients was studied prospectively. Our results showed that 41/87 (47%) of patients presented with trismus, 57/80 (71%) had postoperative trismus, and 41/52 (79%) had trismus 6 months after operation or radiotherapy (trismus defined as a maximum mouth opening of ≤35mm). Men and those who drank a lot of alcohol were less likely to have trismus after treatment. QoL variables showed that pain, eating, chewing, taste, saliva, social functioning, social contact, and dry mouth were significantly more impaired in the trismus group than among those without trismus. Postoperative differences in QoL between the two groups highlighted problems with social function and role-playing, fatigue, activity, recreation, and overall reduction in QoL. Women, and those who do not drink alcohol, are at particularly high risk of developing trismus, and, to prevent it and treat it, patients may benefit from multidisciplinary management at an early stage during treatment.
2011-07-25T00:00:00ZSCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.Symonds, R PDavidson, Susan EChan, SReed, N SMcMahon, TRai, DHarden, SPaul, Jhttp://hdl.handle.net/10541/2291682019-08-30T13:35:15Z2011-10-01T00:00:00ZSCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.
Symonds, R P; Davidson, Susan E; Chan, S; Reed, N S; McMahon, T; Rai, D; Harden, S; Paul, J
The aim of the study was to determine the response rate and response duration of cervical cancer previously treated by cisplatin (with or without radiation) to a combination of docetaxel and gemcitabine. Secondary endpoints were assessment of toxicity and quality of life (QoL) of patients receiving the treatment.
2011-10-01T00:00:00ZGuidelines for preclinical and early phase clinical assessment of novel radiosensitisers.Harrington, K JBillingham, L JBrunner, T BBurnet, N GChan, C SHoskin, PMackay, Ranald IMaughan, T SMacdougall, JMcKenna, W GNutting, C MOliver, APlummer, RStratford, I JIllidge, Timothy Mhttp://hdl.handle.net/10541/2292322019-08-30T13:38:35Z2011-08-23T00:00:00ZGuidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
Harrington, K J; Billingham, L J; Brunner, T B; Burnet, N G; Chan, C S; Hoskin, P; Mackay, Ranald I; Maughan, T S; Macdougall, J; McKenna, W G; Nutting, C M; Oliver, A; Plummer, R; Stratford, I J; Illidge, Timothy M
2011-08-23T00:00:00Z